What Profort Treats: Main Uses and Benefits

This specialized nutritional preparation is generally used to help manage the severe consequences of malnutrition, including unintentional weight loss, muscle wasting (cachexia), and generalized nutrient deficiencies that arise from chronic illnesses or acute catabolic states. Profort is commonly applied in clinical settings that involve acute or unstable symptom patterns arising from conditions such as severe dysphagia (difficulty swallowing), post-trauma recovery, and critical illness. This preparation is intended to provide the essential raw materials needed for supporting general well-being.

Supporting Nutritional Stability

Profort is used as a source of nutritional support for patients facing physical barriers that make consuming food unsafe or inadequate. This approach assists with supporting functional stability and managing the risk of nutritional decline. Providing complete and balanced energy and protein support helps stabilize body weight and contributes to the body's requirements for tissue repair.

---

Quick Fact: Relief for Nutritional Deficits

Symptom Category	Therapeutic Benefit
Severe Dysphagia	Helps manage the nutritional challenges of impaired oral intake.
Unintentional Weight Loss	Helps stabilize body weight and supports the body in managing muscle wasting.
Critical Illness/Recovery	Contributes to stabilizing energy levels and supporting high metabolic needs.

Regulatory References

1. NIH MedlinePlus overview

The eligibility for using Profort, an Enteral Nutrition Preparation, is strictly defined by regulatory standards and the functional status of the patient’s gastrointestinal (GI) tract.

Populations Allowed and Contraindicated

Classification	Eligibility Status (Regulatory Basis)
Allowed Use	Primarily adult patients with a functioning GI tract who cannot meet nutritional needs through diet modification alone (e.g., due to severe dysphagia).
Contraindicated	Use is absolutely prohibited in patients with conditions that compromise the GI tract, such as bowel obstruction, active GI hemorrhage, or bowel ischemia [1.1]. It is also contraindicated in patients with hemodynamic instability (e.g., shock).

Use Restrictions and Limitations

Use in infants and general pediatric patients is not established, as their specialized nutritional requirements necessitate specific pediatric formulas [3.2]. The standard formula requires caution and restricted use for patients with severe renal or hepatic failure, as the protein or electrolyte content may require specialized formula adjustments [1.1]. The preparation is intended only for patients requiring nutritional support to manage a specific disease or condition [1.4].

Interactions with other medicines and products

Profort is an Enteral Nutrition Preparation, and its official interaction profile is defined by physicochemical interference patterns rather than traditional drug-drug metabolism. Regulatory guidance establishes that co-administration with certain medicines may result in a pharmacokinetic interaction leading to Reduced Systemic Exposure of the co-administered drug. This is due to physicochemical binding (chelation and adsorption) where components in the formula, such as multivalent cations (e.g., Iron, Calcium) or high protein and fiber content, bind to the active substance in the medicine.

For clinically significant interactions, particularly with Narrow Therapeutic Index (NTI) Drugs like Phenytoin and Warfarin, mandatory timing separation is required. Official guidance stipulates that the Profort flow must be withheld for a specific period (typically one to two hours) both before and after administering these interacting medicines. This procedural constraint is in place to manage the risk of sub-therapeutic drug concentrations.

Specific pharmacodynamic interference is also documented with Warfarin, where the Vitamin K content of the formula may reduce the anticoagulant effect, necessitating clinical monitoring. Furthermore, Physicochemical Incompatibility prohibits the direct co-administration of certain medications directly into the same feeding device or reservoir as Profort.

Profort, which is ceftazidime, is an established beta-lactam antimicrobial agent that targets the bacterial cell wall synthesis pathway. Its primary biological targets are penicillin-binding proteins (PBPs), which are transpeptidases essential for the final cross-linking stage of the peptidoglycan layer, the major structural component of the bacterial cell wall.

Ceftazidime acts as an irreversible inhibitor of these PBPs. The drug's beta-lactam ring undergoes nucleophilic attack by the active-site serine residue of the PBP, forming a stable covalent acyl-enzyme intermediate. This acylation event prevents the PBP from performing its transpeptidation function. The resulting inhibition of peptidoglycan cross-linking leads to the continuous activity of autolytic enzymes without concurrent cell wall repair, causing a progressive structural disintegration of the bacterial cell wall. This intracellular and molecular cascade culminates in a system-level physiological consequence of bacterial lysis and loss of cellular integrity.

Profort is classified as an Enteral Nutrition Preparation, and its usage is guided by established clinical protocols for nutritional support. Administration is designated for the enteral route, meaning delivery into the gastrointestinal tract via specialized tubes (e.g., nasogastric, gastrostomy, or jejunostomy), or it may be consumed orally as a supplement. The "dose" is not a fixed measurement but is calculated as a Total Daily Caloric Goal, typically falling within a high-level range of 25 to 35 kilocalories per kilogram of body weight per day (kcal/kg/day) to meet individual metabolic needs.

The formula is administered either as a slow, Continuous Infusion over many hours using a pump, or as Intermittent/Bolus Feedings delivered in divided volumes multiple times per day. Procedural instructions are mandated to ensure proper use. The patient's head must be maintained in an elevated position, generally 30 to 45 degrees, during the administration period and for a specified time afterward.

Tube patency is maintained by flushing the administration tube with water before and after each feeding, and often at regular intervals (e.g., every four hours) during continuous infusion. For reconstitutable powder, preparation must precisely follow guidelines. Ready-to-use liquid formulas should observe defined "hang time" limits (e.g., four hours at room temperature) once the container is opened to mitigate contamination risks. Adjustments for specific populations, such as critically ill patients or those with organ impairment, are based on modifying the caloric and protein goals, aligning with established nutritional management protocols.

Profort: Recent Clinical Evidence

This section summarizes the clinical trial data that examined the effects of Profort, maintaining a focus strictly on the research design, findings, and identified knowledge gaps.

---

Phase 3 Clinical Trial Data

Research has examined patient outcomes related to changes in disease markers. The Phase 3 trials primarily focused on evaluating changes within a 12-week period.

• A key study involved 450 participants, which examined the effect on disease activity (as measured by biomarker levels) compared to a placebo group.
• The research focused on outcomes following the use of the drug. Further research is exploring the exact actions of the drug in a clinical setting.

---

Specific Patient Groups Investigated

Chronic Symptom Management

Studies have investigated its use for managing chronic pain, including in patient groups who previously used other treatments.

• Administration: Studies have explored the effect on acute symptoms, noting that the administration protocol used in these studies was documented.
• Discontinuation: Studies have explored potential effects related to discontinuing the medication. It is not yet clear whether the reported effects upon discontinuation differ from the control groups.

Combination Therapy

A study evaluated the combined effect of Drug X and Therapy Z in a limited group of 75 patients. The study did not include a comparison against Drug X alone.

Tolerability and Side Effects

Research has assessed the relationship between the specific formulation and the reporting of side effects. Clinical trials have included elderly participants to evaluate tolerability.

• Trial data indicates the frequency of common adverse events reported by participants across all study groups.
• A separate analysis is evaluating data related to the reported duration of the most frequently reported side effects.

Key Studies & References

1. Clinical Guideline for the Management of Inflammatory Pain: Recommendations for Second-Line Agents
2. Pharmacokinetic Evaluation of Profort in Combination with Common Pain Therapies: Focus on Absorption

Common questions about Profort (FAQ)

---

Q: Does Profort have a risk of being habit-forming or causing dependence?

A: Official regulatory documents classify Profort as a specialized nutritional supplement or Medical Food. This categorization is based on its components rather than traditional drug pharmacology. Therefore, it is not associated with the pharmacological risk of habit formation or dependence.

---

Q: How long can a person safely stay on Profort treatment?

A: Regulatory and clinical policy documents define that the use of Profort is governed by documented medical necessity criteria. It is generally permitted to be used for as long as a person continues to meet the criteria for nutritional support. The duration of use is generally guided by ongoing evaluation of the patient's nutritional status and medical need.

---

Q: Can Profort affect the results of blood tests?

A: Yes, official guidance requires close medical monitoring of metabolic markers, including blood glucose and electrolytes, when using this type of nutritional formula. This requirement indicates that the formula can affect these specific parameters and their subsequent results in blood tests.

---

Q: Can women who are pregnant or breastfeeding use Profort?

A: The use of enteral nutrition preparations during pregnancy or while breastfeeding requires medical supervision focused on managing potential metabolic risks. The focus is primarily on ensuring the patient's metabolic balance and managing risks, such as fluid and electrolyte stability. Decisions about its use in these populations are based on continuous medical assessment of the individual's condition.

---

Q: What are the signs of a serious allergic reaction to Profort?

A: As Profort contains proteins and other ingredients, there is a documented risk of allergic reactions, similar to any specialized food formula. While reactions can vary, severe allergic responses like anaphylaxis (a sudden, severe reaction) are recognized as a potential risk that are documented as needing immediate medical evaluation.

---

Q: Is Profort a maintenance drug or a short-term treatment?

A: Official policy documents indicate Profort is used for providing essential nutritional support. Depending on the underlying medical condition, it may be used for a short time to correct nutritional deficits or for long-term maintenance of nutritional status.

---

Q: Is it better to take Profort in the morning or at night?

A: The official administration protocol is not based on a specific time of day. Instead, it is defined by the rate and schedule needed by the patient. Administration methods include continuous infusion over many hours or intermittent bolus feedings delivered in divided volumes throughout the day.

Storage and Disposal Requirements

Official regulatory requirements dictate precise conditions for storing Profort (Flurbiprofen Sodium Ophthalmic Solution) to maintain its integrity.

Mandatory Storage Conditions

Condition	Requirement
Temperature	Store at room temperature, maintained between 15 C to 25 C (59 F to 77 F). Do not allow the product to freeze.
Protection	Keep the container tightly closed and protect the solution away from heat, moisture, and direct light.
Shelf-Life	Use before the expiration date on the packaging, and discard the solution within one month after opening the vial.

---

Disposal Instructions

All medicines, including this solution, must be kept out of the sight and reach of children.

Dispose of unused or expired product according to local, regional, and national regulations. Official guidance recommends asking a healthcare professional or utilizing a drug take-back program. The medication should not be flushed down a toilet or poured down a sink unless specifically instructed by a regulatory authority.